NEW YORK, May 22 (Reuters) - Drug maker Wyeth WYE.N said on Tuesday the U.S. Food and Drug Administration approved its low-dose oral contraceptive Lybrel, designed to eliminate a woman's monthly period.
In a statement, Wyeth said Lybrel, which will be available by prescription, is expected in U.S. pharmacies in July 2007.
OTTAWA (Reuters) - Research In Motion posted a big jump in profit and issued an even stronger outlook on Thursday, as sturdy demand from holiday shoppers helped the BlackBerry maker fend off the competition.
"I told Michelle when we got here that in six months my poll numbers will start crashing," says President Obama. He's not worried -- yet. Full Article
The Pentagon burns through $5 million in borrowed money every hour in Afghanistan and the amount is expected to more than double once additional troops are deployed. Commentary
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
